Neurocrine Acquires Wyeth’s Financial Interest in Indiplon
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 46 (Table of Contents)
Published: 4 Apr-2004
DOI: 10.3833/pdr.v2004.i46.815 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Neurocrine Biosciences entered into an agreement with Wyeth to acquire Wyeth’s financial interest worthing up to US$95 M in the late-stage insomnia treatment, indiplon...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS